“这项研究表明，对于双药治疗反应不理想的患者，延迟引入第三种药物不仅能帮助更多患者达到检测不到的微小残留病状态，还大幅降低了感染和3级中性粒细胞减少的风险，” 该研究的主要报告者、德克萨斯大学MD安德森癌症中心的Mahesh Swaminathan博士在2025年ASH年会上指出。“这为需要更强效治疗的患者提供了一个兼顾疗效与安全性的新选择。” ...

For patients who have chronic lymphocytic leukemia (CLL), experiencing Richter transformation with central nervous system ...

A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

What Is Chronic Lymphocytic Leukemia? Chronic lymphocytic leukemia (CLL) is a cancer that affects a type of white blood cell called a "lymphocyte." Lymphocytes help your body fight infection. They're ...

5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, ...